Sartorius Aktiengesellschaft
Research Sartorius Aktiengesellschaft (SRT3) on Bullrun: valuation model: 31.0% overvalued, market cap EUR 17.03B, P/E 86.8, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSRT3
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Valuation signal31.0% overvalued
- Market capEUR 17.03B
- P/E86.8
- Dividend yield0.3%
- Financial periodQ2 2026
- RevenueEUR 911.80M
- Net incomeEUR 65.90M
- Free cash flowEUR 92.10M
- Gross margin47.5%
Valuation Snapshot
Bullrun's latest valuation model marks Sartorius Aktiengesellschaft as 31.0% overvalued; latest market cap is EUR 17.03B; P/E is 86.8; dividend yield is 0.3%.
Peer valuation comparison
Latest P/E is 86.83x versus a Healthcare sector median of 24.46x (255.0% above).
Latest dividend yield is 0.29% versus a Healthcare sector median of 2.11% (86.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 3.54B | EUR 218.00M | n/a | 46.3% | n/a | EUR 541.40M | EUR 4.28B | EUR 2.71B |
| FY2024 | EUR 3.38B | EUR 119.40M | n/a | 45.1% | n/a | EUR 813.40M | EUR 4.56B | EUR 2.76B |
| FY2023 | EUR 3.40B | EUR 205.50M | n/a | 46.2% | n/a | EUR 379.20M | n/a | n/a |
| FY2022 | EUR 4.18B | EUR 678.10M | n/a | 52.2% | n/a | EUR 165.90M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 17.03B | 86.8 | 0.3% | 0.74 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.74 EUR, yield 0.3%.
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Sartorius Aktiengesellschaft overvalued or undervalued?
Bullrun's valuation model currently marks Sartorius Aktiengesellschaft as 31.0% overvalued.
What is Sartorius Aktiengesellschaft's market cap?
Sartorius Aktiengesellschaft's market capitalization is EUR 17.03B.
What is Sartorius Aktiengesellschaft's P/E ratio?
Sartorius Aktiengesellschaft's price-to-earnings (P/E) ratio is 86.8.
Does Sartorius Aktiengesellschaft pay a dividend?
Sartorius Aktiengesellschaft has a dividend yield of 0.3%.
What does Sartorius Aktiengesellschaft do?
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid.